Objective: To analyze operative outcomes and mid-term results after isolated aortic valve replacement (AVR) in low-flow, low-gradient aortic stenosis (LFLG AS) by comparing the 2 subcategories (classic low-flow, low-gradient aortic stenosis [CLFLG] and paradoxical low-flow, low-gradient aortic stenosis [PLFLG]).
Kaplan-Meier survival curves of patients undergoing aortic valve replacement for LFLG AS or PLFLG AS performed with the log-rank test (P ¼ .01). The number of patients at risk in each group at the different time frames also is provided. Median survival was 13.1 years (95% confidence interval 8.0-13.1) for the PLFLG group and 5.5 years (95% confidence interval 5.2-7.9) for the CLFLG group (P ¼ .001).
Central Message
Aortic valve replacement provides good symptomatic relief and mid-term survival benefit and therefore, is worth offering to symptomatic patients with low-flow, low-gradient aortic stenosis who meet the current guidelines criteria for surgery.
Perspective
Low-flow, low-gradient aortic stenosis (LFLG AS) is becoming an increasingly complex concept. Aortic valve replacement is associated traditionally with a high mortality in patients with classic LFLG AS and is controversial in those with paradoxical LFLG AS. We report in-hospital and mid-term mortality for both LFLG AS groups and the excellent functional status among survivors. Further studies are necessary to integrate the LFLG AS into the current guidelines.
See Editorial Commentary page 443.
Since the introduction of low-flow, low-gradient aortic stenosis (LFLG AS), the prognosis and outcomes of these patients after aortic valve replacement (AVR) have generated increasing interest in the literature. It is estimated that 30% of patients in whom the aortic valve area (AVA) meets the criteria of severe aortic stenosis (AS) have transvalvular gradients in the range of moderate aortic stenosis (<40 mm Hg) due to a reduced transvalvular flow. This entity is known as LFLG AS and can be subdivided into 2 categories depending on the left ventricular ejection fraction (LVEF, Video 1). 1, 2 The classical or true LFLG pattern is seen in patients with dilated left ventricles and reduced LVEF. The paradoxical LFLG pattern is present in patients with preserved LVEF and paradoxically low peak and mean transaortic gradients. They have reduced stroke volume index (SVi) values (<35 mL/ m 2 ) through a combination of mechanisms that include concentric remodeling, abnormal ventriculoaortic impedance, and abnormal longitudinal left ventricular (LV) function. [1] [2] [3] It is important to distinguish these cases from those with just moderate AS and nonrelated myocardial dysfunction as primary pathology (pseudo-severe AS). In this entity, the valve might appear stenotic as result of the inability of the ventricle to generate adequate force to fully open it. Dobutamine stress echocardiogram (DSE) is useful in differentiating between the two. In patients with severe AS, the inotropic effect of dobutamine increases the flow through a fixed valve orifice, resulting in increased peak velocities and hence the gradient, whereas in pseudo-severe AS the dobutamine inotropic effect improves opening of the valve, hence increasing the AVA by >0.2 cm 21,2 ; therefore, the gradient does not increase.
The surgical mortality for patients with classic low-flow, low-gradient aortic stenosis (CLFLG AS) has decreased in recent decades; however, these patients continue to have a greater morbidity and mortality after AVR compared with patients with normal-flow, high-gradient aortic stenosis (NFHG AS). [4] [5] [6] [7] Patients with paradoxical low-flow, low-gradient aortic stenosis (PLFLG AS) have been reported to have a worse prognosis than those with moderate AS or severe NFHG AS, although they seem to have better prognosis after AVR than the patients with CLFLG AS. 1, 2 The objective of the study was to determine the operative and mid-term outcomes of surgical intervention in the 2 LFLG AS subgroups in our unit. Therefore, we analyzed operative outcomes and mid-term results (clinical status and mortality) after isolated AVR in patients with CLFLG AS compared with PLFLG AS (Video 1).
MATERIALS AND METHODS Patient Selection and Data Collection
A retrospective analysis of prospective electronically collected data of all patients with AS who underwent isolated AVR in Morriston Regional Cardiac Centre from January 2001 to April 2014 was performed. Preoperative characteristics, cardiovascular risk factors, postoperative complications, and in-hospital mortality were recorded prospectively in our database, Patients Administration and Tracking System.
All patients had a detailed preoperative echocardiography in our center to assess the severity of the AS (AVA and gradients) and to classify it into the 2 categories according to the LVEF. DSE was performed in 25% of the patients with CLFLG AS to confirm the diagnosis or to assess the myocardial reserve according to the referring cardiologist criteria. The low-dose protocol with an increasing infusion of dobutamine starting at 5 mg/kg/min to a final dose of 20 mg/kg/min was used. Atropine was required in some of the cases to reach the targeted heart rate. All DSEs performed were considered optimal and all demonstrated myocardial reserve before surgery. We do not use multidetector computed tomography in our center for routine assessment of these patients. Indications for AVR were established by the operating surgeon and the referring cardiologist in the preoperative clinic visits and were made on the basis of a combination of the symptomatic status of the patient and degree of aortic stenosis (Tables 1 and 2 ) according the current guidelines.
Mid-term follow-up consisted of routine clinic visits annually from 6 weeks of discharge or clinical letters from cardiologist on those who were discharged from our follow-up. We also performed telephone interviews of those patients who were not seen by any specialist in the previous year to determine survival and functional class. The follow-up results described in the study were obtained from January to July 2015 by 1 of the 2 methods described previously.
Postoperative echocardiograms were performed at the clinic visits at 6 weeks after discharge for all patients and then annually for those who remained on our follow-up system. For this analysis we have used the last postoperative echocardiogram available for each patient (a generalized linear mixed model was used to compare them with the preoperative echocardiograms). LVEF, AVA, and gradients were recorded.
The data used in this study were approved by the institutional review board, which deemed an individual consent form was not needed because no patient-identifiable information was used.
For this study, we identified 2 groups: (1) CLFLG AS: classical LFLG AS with reduced LVEF (n ¼ 66, 33%); and (2) PLFLG AS: paradoxical LFLG AS with normal LVEF (n ¼ 132, 67%)
Statistical Methods
Continuous variables are expressed as mean AE standard deviation or median AE interquartile range (depending on distribution of data), and comparison between groups was performed with the t test/Mann-Whitney U test. Categorical variables are expressed as percentages and compared by the use of c 2 /Fisher exact test as appropriate. A multiple logistic regression model was used to identify the predictors of early mortality and Cox regression was applied to identify the best predictors of late mortality including all the significant variables listed in annexed tables (cut-off at P<.05) (Tables 1-4). The results were expressed as odds ratios (ORs) and hazard ratios with corresponding 95% confidence intervals (CIs).
Because the 2 groups were significantly different with respect to their baseline characteristics, propensity score matching (with a match tolerance of 0.05) was performed (including the preoperative characteristic except echocardiographic parameters) using SPSS 22.0 (IBM Corp, Armonk, , impaired LVEF. After DSE, AVA >1.0 cm 2 , mean gradient remains<40 mmHg. Pulmonary hypertension was defined as pulmonary artery pressure >50 mm Hg measured by echocardiography. Severe ventricular dysfunction was defined as LVEF <30%, moderate ventricular dysfunction was defined as LVEF 30% to 50%, and normal ventricular function was defined as LVEF>50%. Previous neurologic disease was defined as cerebrovascular accident or transient ischemic attack diagnosed before the operation, with or without residual deficits. Postoperative neurologic events was defined as new focal deficit after surgery; either transient ischemic attack or cerebrovascular accident. Long-term ventilation was defined as postoperative ventilation for more than 7 days, including reintubation or tracheostomy. Respiratory complications were defined as acute distress respiratory syndrome or pneumonia during the postoperative period. Finally, gastrointestinal complications were defined as bowel ischemia, bleeding, or laparotomy for any cause during the postoperative period.
RESULTS
We identified 198 patients who fulfilled the inclusion criteria, 66 of them in the CLFLG AS group and 132 patients in the PLFLG AS group. A propensity-matched analysis was done to compare the groups, reducing the cohort to 116 patients (58 in each group).
Patients with CLFLG AS presented with greater functional NYHA class III-IV, a greater incidence of permanent atrial fibrillation, and pulmonary hypertension (Table 1 ). In contrast, in the PLFLG AS group, there were more female patients, a greater incidence of systemic hypertension, previous neurologic events, and chronic Type of prosthesis used in the aortic valve replacement are listed. CLFLG, Classic low-flow, low-gradient; PLFLG, paradoxical low-flow, low-gradient. Postoperative outcomes in patients undergoing isolated aortic valve replacement for aortic stenosis in different groups. CLFLG, Classic low-flow, low-gradient; PLFLG, paradoxical low-flow, low-gradient; IABP, intra-aortic balloon pump; ARDS, adult respiratory distress syndrome; GI, gastrointestinal.
renal failure on hemodialysis. Presentation in CCS class III-IV angina also was more common in this group (Table 1) . Median logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) was 13.5 (Q1 5.5, Q3 20.4) in the CLFLG AS group and 5.1 (Q1 3.3, Q3 9.1) in the PLFLG AS group (P ¼ .001) ( Table 1) . After the propensity score matching, the incidence of these preoperative characteristics was equivalent in the 2 groups (Table 1) .
Echocardiographic analysis showed greater mean gradients in the PLFLG AS group but smaller AVA in the CLFLG AS group. Pulmonary hypertension was significantly more common in the CLFLG AS group. As per definition, all the patients in the PLFLG AS group had a preserved LVEF, whereas those in the CLFLG AS had an impaired LVEF (moderate 61%, severe 39%) ( Table 2 ).
The propensity score matching did not include the LVEF category as this defines the 2 groups. Pulmonary hypertension remained more frequent in the CLFLG group after the matching ( Table 2 ).
The choice of prosthesis used for the AVR was based on patients and surgeons' preferences. 88% had a stented bioprosthesis and 12% a bileaflet mechanical prosthesis. Choice of mechanical prosthesis was significantly greater in the PLFLG AS group (Table 3) .
Prosthesis sizes varied from 18 to 32 mm (97% between 21 and 27 mm). Enlargement of the aortic root with a pericardial patch to implant a bigger valve was performed in 6% of the patients. Size 19 mm was used more frequently in the CLFLG AS group. A total of 56 patients (28%) received a valve sized <23 mm (41 patients in the PLFLG AS group and 15 patients in the CLFLG AS group). Inhospital mortality for these patients was 4% (2 patients, both in the CLFLG AS group, P ¼ .06) and 23% during the follow-up (13 patients, 5 in the CLFLG AS and 8 in the PLFLG AS group, P ¼ .58) ( Table 4 ). There were no significant differences on the aortic crossclamp and cardiopulmonary bypass times between the 2 groups.
Overall in-hospital mortality for all LFLG patients who underwent isolated AVR was 2% (5 deaths), categorized as follows: 1 death (20%) was cardiac related and 4 deaths (80%) secondary to sepsis. In-hospital mortality was 3% in the CLFLG AS group compared with 2% in the PLFLG AS (P ¼ .08). In the matched cohort, all in-hospital deaths (3 patients, 3%) occurred in the CLFLG group (P ¼ .08) ( Table 4) .
Postoperative respiratory complications were greater in the CLFLG AS group. These patients had a greater rate of mortality, with 2 of them dying in the hospital. The greater incidence of respiratory complications for the CLFLG group was maintained in the matched cohort (Table 4) .
We did not identify any preoperative characteristics as risk factor for in-hospital mortality in any of the groups in the univariable analysis (P <.05), not even in the matched population, and therefore it was not possible to apply a logistic regression that included all the significant risks factors at the univariable analysis. This was explained by the insufficient events to detect predictors due to the low inhospital mortality rate for the cohort.
Late Outcomes
Follow-up was up to 13 years, with a median of 3.7 AE 3.3 years (range 0.1-13.0 years). There were only 3 patients lost to follow-up (2%). Overall 1-year mortality was 14%. It was significantly greater in the CLFLG AS group (29% vs 6% in the PLFLG AS, P ¼ .01). At 5 years, overall mortality was 48%. It also was greater in the CLFLG AS group (64% vs 39%, P ¼ .001). These differences persisted in the matched cohort (Table 4 , Figures 1 and 2) . Median survival calculated according to Kaplan-Meier analysis was 13.1 years (95% confidence interval [CI], 8.0-13.1) for the PLFLG group and 5.5 years (95% CI, 5.2-7.9) for the CLFLG group (P ¼ .001) (Figure 1 ). In the matched cohort, the median survival for the PLFLG group was 8.3 years (95% CI, 3.5-13.2) and 3.7 years (95% CI, 1.2-4.2) for the CLFLG group (P ¼ .02) (Figure 2) .
A total of 58 patients (29%) died during the follow-up. Causes of death were categorized as follows: 14 (24%) were cardiac related, 6 (10%) were due to cancer, 9 (15%) were secondary to stroke, 2 p (4%) were due to respiratory problems, 3 (6%) were due to renal disease, 1 (2%) was due to sepsis, and 9 (15%) were due to other causes. We were not able to identify the cause of death in 14 patients (24%).
For the whole cohort, Cox regression identified as risk factors for late mortality CLFLG AS (P ¼ .001, OR; 2.5, 95% CI, 1.5-4.2) and previous myocardial infarction (P ¼ .001, OR, 2.6; 95% CI, 1.3-5.1). Chronic renal failure with previous hemofiltration was identified by Cox regression as a risk factor for late mortality in the PLFLG group (P ¼ .004, OR, 1.2; 95%, CI 0.1-0.5). No preoperative characteristics were identified as predictors for late mortality in the CLFLG group by Cox regression despite including the preoperative characteristics that were significant in the univariable analysis (female sex, P <.05).
We were not able to identify any predictors of late mortality in the matched cohort, because none of the preoperative characteristics were significant in the univariable analysis.
Clinical status was excellent in those patients who survived. Among the survivors at follow-up, 90% were found to be in NYHA functional class I-II and only 10% (14 patients, 6 in the CLFLG AS group and 8 in the PLFLG AS group) were in NHYA class III. Therefore, AVR provided efficient symptomatic relief, as 68% of the patients in the CLFLG group and 47% in the PLFLG group presented in NHYA class III-IV. The generalized linear mixed model was used to assess the relationships of NYHA class with LFLG over the follow-up time (median 1.8 AE 3.2 years, range 0.1-1.7 years). The odds of the symptomatic NYHA decreased by 38% in the CLFLG group per year (OR, 0.62; 95% CI, 0.3-1.3; P >.05) and by 32% (OR, 0.68; 95% CI, 0.5-0.9, P ¼ .006) in the PLFLG group per year.
Twenty patients (14%) were in atrial fibrillation and 2% in paced rhythm. The incidence of stroke was 1%, all of whom were in the CLFLG AS group.
A few patients were readmitted to the cardiology ward in our hospital with symptoms of heart failure in the years after their operation. We recorded a total of 25 readmissions (13%), 18 of them (72%) in the CLFLG group (P ¼ .001). Two patients were treated for prosthetic endocarditis. We did not find any relationship between the readmissions and the size of the implanted valve.
The analysis of postoperative echocardiograms demonstrated no differences in the postoperative valve gradients or area (CLFLG AS: mean gradient 9.8 AE 3.2 mm Hg, AVA 1.6 AE 0.7 cm 2 ; PLFLG AS: mean gradient 10.4 AE 5.5 mm Hg, AVA 1.5 AE 0.5 cm 2 ). No cases of patient-prosthesis mismatch were seen in our cohort, not even for the 19 mm size implanted.
The ventricular function remained preserved in 81% of the PLFLG AS group, and 51% of the patients in the CLFLG AS group had an improvement in their LVEF, from severe to moderate dysfunction (13%) or to normal function (11%) and from moderate dysfunction to normal function (27%). A generalized linear mixed model was used to assess the relationships of LVEF with LFLG over the follow-up time (median 6 AE 11 months, range 1-120 months). The odds of LVEF improvement in the CLFLG group increased by 4.5% per month (OR, 1.04; 95% CI, 0.9-1.1; P >.05).
DISCUSSION
It is well established in previous reports that patients with LFLG AS, especially those with CLFLG AS, have poor quality of life and very high mortality (as high as 70%-80% at 3 years) with medical treatment. 1, 2, [8] [9] [10] [11] In our series we demonstrated remarkably low in-hospital postoperative mortality. 5, 7, 12 However, we had high mid-term mortality, especially for the CLFLG AS, consistent with previous reports. [4] [5] [6] [7] [12] [13] [14] [15] The fact that we did not identify any predictors of in-hospital mortality was not surprising, given the low in-hospital mortality rate in our cohort. We confirmed a significant improvement in symptoms and quality of life among survivors.
1,2 Therefore our data, although obtained from a purely observational and retrospective study, suggests that AVR offers both prognostic and symptomatic benefits in both subgroups of LFLG AS. We therefore suggest AVR should be offered for patients with symptomatic LFLG AS.
The significant difference in the logistic EuroSCORE between the groups was not surprising, based on the different preoperative characteristics. These differences were reflected in a greater in-hospital and mid-term mortality rate for the CLFLG AS. Despite eliminating the preoperative differences by performing a matched analysis both inhospital and long-term differences in mortality were maintained.
We have not performed transcatheter aortic valve implantation (TAVI) for patients with LFLG AS yet (although we started the program in 2009), and therefore we cannot assess the potential benefit that these patients would obtain based on the larger AVA and lower gradients that the TAVI prosthesis offers in comparable sizes. On the other hand, we have not found any relationship between the size of the valve implanted and both in-hospital and long-term mortality, not even for sizes of valves<21 mm. Future studies are needed to confirm the potential benefits of TAVI as well as the use of sutureless prosthesis in this cohort of patients.
There was significant improvement in the ventricular function in patients with CLFLG as assessed by postoperative echocardiography, which also was reflected in clinical improvement in patients' functional class. This gives reassurance that surgical intervention for this group of patients was significantly beneficial.
Although it initially was debated whether PLFLG AS was a stage in the progression from moderate to severe AS, current data suggest that it is actually a distinct condition and not a stage in the evolution of NFHG AS. The intrinsic myocardial dysfunction, although not translated in LVEF impairment, may explain the greater mortality compared with the NFHG AS. 10, 11, [16] [17] [18] [19] [20] [21] [22] [23] These patients have a better prognosis if treated surgically, although they have a greater operative risk, given their intrinsic myocardial dysfunction and the increasing risk of having mismatch due to their small ventricular cavity resulting from severe hypertrophy. 1, 2 Discrepancies among previous studies on PLFLG AS highlight the importance of the correct diagnosis of this entity, because any minimal measurement error on the diagnostic echocardiography could label wrongly a different entity of AS with a complete different prognosis and outcome after AVR (ie, moderate AS with underestimated SV and AVA or severe AS with underestimated gradient). 20 There is a role for multidetector computed tomography and quantification of valve calcification when the echocardiography is not conclusive. 17, [20] [21] [22] [23] Current American College of Cardiology/American Heart Association guidelines recommend AVR for symptomatic CLFLG AS (Class IIa, Level B) whereas the European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommend AVR (Class IIa, Level C) in patients with LV contractile reserve. For the PLFLG AS, the Current American College of Cardiology/ American Heart Association and ESC/European Association for Cardio-Thoracic Surgery guidelines recommend AVR for symptomatic patients (Class IIa, Level C) only if the clinical, anatomic and hemodynamic data support the valve stenosis as the most likely cause of the symptoms. 24, 25 There is still uncertainty regarding which subsets benefit from surgery and the exact timings and thresholds for intervention and hopefully better indications will be further addressed in the near future guidelines.
Our study has the limitations of being retrospective and purely observational. We did not have a control nonsurgical group; hence, we cannot formulate firm conclusions on the appropriateness of surgical treatment. Because we did not perform DSE in all patients with reduced EF, AS, and low gradients, the indication for AVR was based on one of the following criteria: lack of an alternative pathology to explain symptoms, morphologic assessment by computed tomography or transesophageal echocardiography, and/or lack of evidence of mid-wall late gadolinium enhancement by cardiac magnetic resonance to suggest a dilated cardiomyopathy. However, we provide a large number of patients with LFLG AS (especially PLFLG AS) undergoing isolated AVR and specifically look at short-and mid-term clinical outcomes.
CONCLUSIONS
Isolated AVR in LFLG AS can be performed with acceptable surgical mortality, comparable with that observed in patients with NFHG AS. However, as previously published, our series confirm that this group of patients, especially the CLFLG group, has a significantly greater mid-term mortality after AVR compared with NFHG AS. In the absence of large randomized controlled studies we surmise that, based on the good functional class of survivors and the low inhospital mortality, AVR can be offered to patients with LFLG AS (Video 1).
